JAML and cancer: Specific surface markers proposed to identify neutrophil subsets in cancer include CD101 and CD177 [174, 175], which are associated with cancer regression, and CD117, PDL1, CD170, LOX1, CD84 and JAML [176], which are associated with T cell immunosuppression and cancer progression.